Meeting
2023 ASCO Annual Meeting
The final analysis of a phase I/II study of nivolumab, ipilimumab combined with nintedanib in advanced non-small cell lung cancer.
Authors
Sonam Puri
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Sonam Puri , Tawee Tanvetyanon , Ben C. Creelan , Michael Rahman Shafique , Andreas Nicholas Saltos , Alberto Chiappori , Eric B. Haura , Ram Thapa , Dung-Tsa Chen , Theresa A. Boyle , Scott Joseph Antonia , Jhanelle Elaine Gray
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03377023
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9102)
DOI
10.1200/JCO.2023.41.16_suppl.9102
Abstract #
9102
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC.
First Author: Sonam Puri
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2019 Gastrointestinal Cancers Symposium
Multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for second line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
First Author: Nadja M Meindl-Beinker
Poster
2024 ASCO Annual Meeting
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon